373 related articles for article (PubMed ID: 23475104)
1. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Chan JA; Mayer RJ; Jackson N; Malinowski P; Regan E; Kulke MH
Cancer Chemother Pharmacol; 2013 May; 71(5):1241-6. PubMed ID: 23475104
[TBL] [Abstract][Full Text] [Related]
2. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
[TBL] [Abstract][Full Text] [Related]
6. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
[TBL] [Abstract][Full Text] [Related]
7. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Joka M; Boeck S; Zech CJ; Seufferlein T; Wichert Gv; Licht T; Krause A; Jauch KW; Heinemann V; Bruns CJ
Anticancer Drugs; 2014 Oct; 25(9):1095-101. PubMed ID: 25029236
[TBL] [Abstract][Full Text] [Related]
8. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Amato RJ; Flaherty AL; Stepankiw M
Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
[TBL] [Abstract][Full Text] [Related]
10. Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Toffalorio F; Spitaleri G; Catania C; Dal Zotto L; Noberasco C; Delmonte A; Santarpia M; Vecchio F; Brunelli V; Rampinelli C; Barberis M; Fumagalli C; Zucchetti M; Zangarini M; Diena T; Danesi R; de Braud F; De Pas T
Oncologist; 2014 Apr; 19(4):344-5. PubMed ID: 24674875
[TBL] [Abstract][Full Text] [Related]
11. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
12. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
16. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Ooka Y; Chiba T; Ogasawara S; Arai K; Suzuki E; Tawada A; Yamashita T; Kanai F; Kaneko S; Yokosuka O
Invest New Drugs; 2014 Aug; 32(4):723-8. PubMed ID: 24599799
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
Sho T; Nakanishi M; Morikawa K; Ohara M; Kawagishi N; Izumi T; Umemura M; Ito J; Nakai M; Suda G; Ogawa K; Chuma M; Meguro T; Nakamura M; Nagasaka A; Horimoto H; Yamamoto Y; Sakamoto N
Drugs R D; 2017 Sep; 17(3):381-388. PubMed ID: 28573606
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Hubbard JM; Kim G; Borad MJ; Johnson E; Qin R; Lensing J; Puttabasavaiah S; Wright J; Erlichman C; Grothey A
Invest New Drugs; 2016 Feb; 34(1):96-103. PubMed ID: 26581401
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
